Analyst consensus rating
Compass Therapeutics Analyst Rating: none
Direct answer
Compass Therapeutics's consensus rating is none.
11 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $5.45.
Forecast evidence checked October 17, 2026.
Get free Compass Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.86
- Average price target
- $5.45
- High price target
- $12.00
- Low price target
- $1.00
- Low target gap
- +16.3%
- Target upside
- +534.3%
- High target gap
- +1,295.3%
- Target range width
- 1,279.1%
- Consensus rating
- none
- Analysts
- 11
- Evidence date
- October 17, 2026
- Valid through
- October 24, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Compass Therapeutics?
Compass Therapeutics has a verified none consensus. The same dataset has an average price target of $5.45.
How far are Compass Therapeutics's low and high targets from the recorded price?
The low target implies +16.3%, while the high target implies +1,295.3%.
How many analysts are included in Compass Therapeutics's consensus?
The verified consensus includes 11 analysts.
How is Compass Therapeutics's target upside or downside calculated?
The average target of $5.45 is divided by the recorded price of $0.86, then one is subtracted to produce +534.3%. This does not guarantee a future return.
When was Compass Therapeutics's analyst forecast verified?
The data was verified on 2026-10-17. The dataset is valid through 2026-10-24.